Floatz logo

Mb-Cart2019.1

B-cell Non Hodgkin Lymphoma

Miltenyi Biomedicine GmbHPhase 1Active
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

316 Active assets in the B-cell Non Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
VINDESINE
Children's Cancer Group, China
Phase 4BBB
Odronextamab
University of Birmingham
Phase 3BBB
cc-5013
Shanghai Junshi Bioscience Co., Ltd.
Phase 4BBB
METHOTREXATE
Children's Cancer Group, China
Phase 4BBB
Cytosin-Arabinosid
Children's Cancer Group, China
Phase 4BBB

View all 50 →

Same molecule, other indications

Mb-Cart2019.1 is also rated in:

CAR T Cell TherapyDormant
B
Indicative ·
60 / 100
View asset →
diffuse large B-cell lymphomaDormant
CCC
Indicative ·
53 / 100
View asset →
multiple sclerosisDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →